Physician profile
Nader Armanious
NPI 1902023666
$2,025.25
in general payments reported to CMS, 2019-2025
26 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $59.66 · 2021: $361 · 2022: $354 · 2023: $475 · 2024: $306 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075 · Education: $1.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.47 |
| Education | $1.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.73 | 2021-2025 | Vraylar |
| Sk Life Science, INC. | $361.83 | 2021-2024 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $220.86 | 2023-2025 | Nuedexta, Rexulti |
| Livanova USA, INC. | $135.96 | 2019-2022 | |
| Allergan, INC. | $84.20 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $66.42 | 2019-2022 | |
| Lilly USA, LLC | $59.77 | 2020-2025 | Amyvid, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.67 | 2024-2025 | Caplyta |
| Eisai INC. | $53.62 | 2019-2024 | |
| Biogen, INC. | $53.22 | 2019-2021 | |
| Pfizer INC. | $46.49 | 2025 | |
| Ucb, INC. | $39.42 | 2025 | Fintepla |
| Tanabe Pharma America, INC. | $37.16 | 2024-2025 | Radicava |
| Biohaven Pharmaceutical Holding Company LTD. | $35.07 | 2022 | |
| Ani Pharmaceuticals, INC. | $34.59 | 2025 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.10 | 2021 | |
| Jazz Pharmaceuticals INC. | $31.91 | 2022 | |
| Forte Bio-Pharma LLC | $24.53 | 2025 | Tanlor |
| Novartis Pharmaceuticals Corporation | $24.07 | 2021 | |
| Supernus Pharmaceuticals, INC. | $23.70 | 2021 | |
| Neurelis, INC. | $23.61 | 2025 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $17.32 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Armanious listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.